Crispr Therapeutics Highlights Strategic Priorities And Anticipated 2025 Milestones

Reuters
13 Jan
Jan 13 (Reuters) - CRISPR Therapeutics AG ::
*CRISPR THERAPEUTICS HIGHLIGHTS STRATEGIC PRIORITIES AND ANTICIPATED 2025 MILESTONES
*TO ENGAGE REGULATORS ON CTX112 PATH FORWARD, UPDATE MID-2025
*DOSE ESCALATION FOR CTX310 AND CTX320 ONGOING, UPDATES EXPECTED H1 2025
*ONGOING LAUNCH OF CASGEVY DRIVEN BY STRONG PATIENT DEMAND

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 13-JAN-202512:00:00.877 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10